We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 176

Biotech receives $32.5 million for cancer research

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 16 2013

Celator Pharmaceuticals, Inc., a Princeton, New Jersey-based company that develops cancer therapies, has raised $32.5 million in the final closing of

Congress advances pharma supply chain and animal-drug user-fee laws

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 16 2013

The House Energy and Commerce Subcommittee on Health has reportedly approved draft legislation that would change the existing lot-level

Universities abroad experiment with no-fee licensing to drive biotech partnerships

  • Shook Hardy & Bacon LLP
  • -
  • Australia, Canada, European Union, United Kingdom, USA
  • -
  • May 16 2013

Universities in Australia, Canada, Europe, and the United Kingdom have reportedly embraced a 2010 Glasgow University initiative under which companies

NASDAQ Biotechnology Index surpasses all-time high in 1Q13

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 16 2013

The NASDAQ Biotechnology Index reportedly rose in the first quarter of 2013 (1Q13) above levels last seen during the 2000 genomics bubble peakthe

News Bytes - May 16, 2013

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 16 2013

The National Institutes of Health (NIH) Office of Biotechnology Activities proposes revising the "NIH Guidelines for Research Involving Recombinant

Putative class alleges pharma statements about new drug violated securities laws

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 16 2013

Aveo Pharmaceuticals, Inc. and several of its executives have been targeted in a securities class action filed in a federal court in Massachusetts

Annual report reveals need for biotech shift in focus to demonstrate drug value

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 2 2013

According to Ernst & Young's 27th annual biotechnology industry report, the global biotechnology industry has continued its recovery, but small and

Genetic technologies settles infringement suit over non-DNA coding technology

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 2 2013

Genetic Technologies Ltd. (GTG) has reportedly settled a patent infringement lawsuit filed in late 2012 against PreventionGenetics. While the terms

U.S. Senators propose subjecting compounded drugs to federal regulation

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 2 2013

Bipartisan Senate health committee leaders have released draft legislation that would give the Food and Drug Administration (FDA) greater oversight

Michigan Biotech raises $33 million for clinical trials of small molecule therapies

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 2 2013

Ann Arbor-based Esperion Therapeutics, Inc. has reportedly completed a $33-million preferred stock financing that CEO Tim Mayleben said will allow

Current Search

Suggested Facets

Author

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy